Otsuka Dermatitis Candidate Looks Good At Phase III
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.